about
A review of omalizumab for the management of severe asthmaTargeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money.Novel diagnostic approaches and biological therapeutics for intrinsic asthma.Omalizumab in the treatment of asthma.Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting.Omalizumab, an anti-immunoglobulin E antibody: state of the art.Update on optimal use of omalizumab in management of asthma.Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort studyEffectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.Omalizumab: clinical use for the management of asthma.Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience.Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world studyImpact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting.Omalizumab: a review of its use in patients with severe persistent allergic asthma.Omalizumab for severe asthma: efficacy beyond the atopic patient?EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders.'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain.Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.Advances in anti-IgE therapyOmalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study.The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma.Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases.Biologic agents for severe asthma patients: clinical perspectives and implications.Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea.Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up."Real-life" Efficacy and Safety Aspects of Four-year Omalizumab Treatment for Asthma.Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry—Some New ApproachesTolerability of Omalizumab in Asthma as a Major Compliance Factor: 10-Year Follow Up
P2860
Q26741315-6D1F843D-F85C-4D57-8CB7-747890CDBA25Q30360362-A0F0EA36-9329-4615-80C8-77402E110B09Q33904534-E3C1D5B5-E5A5-4C85-B6A0-4F6F306EBC4DQ34029374-BD90398C-7CDF-4AD7-8735-71DFC554D870Q34303895-C65094ED-B354-48E1-BE5D-A8B07C1AC524Q34324456-E48DAAFF-7403-417B-A559-B9B8E5C5F362Q34627039-26AE1397-3E52-4DCB-8120-550C2A30B577Q35095218-A71544BA-D37D-4593-B371-3C6FC99AAAE1Q35117827-D65196E9-DE32-4AB3-BB5B-995BB29C9ACAQ35889211-F4A58137-9938-4788-B91B-B054A85F281EQ36000022-B0A98D51-AD80-41C9-9250-5385E9E0A213Q36055963-A863B078-C496-4D4A-B9F5-DCC07FFBE696Q36113704-60AAEE27-1CF4-41C3-A3FB-4229B8AC1EA6Q36924944-52F46F30-413B-42B6-9D60-F3CA09D60CEAQ37177646-1026DB41-2263-47E7-9AC7-31A2DC0F4CAAQ37428213-9073A8E1-90EA-4A55-A610-65F219F354BEQ38118172-D817B9E1-ADA6-484D-888A-02642C6F6C31Q38201304-FA368E1C-204F-4473-9B5E-9165BA7CCDEFQ38394577-47B0EDE1-40D4-40FB-90CA-3BC0A0C899EFQ38661772-F1688744-E3CB-466B-9025-C4DF16BEC554Q38824499-996E8380-0000-4458-AE59-D3FF71ABB557Q38982481-7A2D7806-EA0E-4844-BABB-A9E7866F8937Q40812061-74654D9B-CAFF-44FB-B035-825FB6F4DB2CQ40889826-C74B4001-E2D6-41FD-86E2-9F4D6F22371CQ41577766-EDE24918-0AAE-46C5-8E70-D351512E9D97Q42637412-097ADACA-4C8D-470B-8729-B4590F31F095Q42693253-B2BAE399-FF2B-4AB8-B19F-6F3D43342D28Q42976598-6D09D163-0485-4D56-BA01-60B58E97B4A9Q47576873-323B4D6A-7F4D-4826-9EF8-0D0783061F1DQ47921576-720128BD-11CD-4464-9E98-3BB54109F4F8Q48071558-CA68DD2F-3A2E-49A1-A824-1F44DCBE5068Q48091478-7EB232FB-BB63-418E-BD36-EF46072918A5Q48266518-B7DB2EAF-2383-4CFC-B8AC-E73C83C2573AQ48484600-FBDA3D90-F0BA-47E4-BDC9-51F93B068678Q50133970-0F51C7BB-41B6-4D83-9873-6E2103D6DE51Q58840803-6FE51480-A831-4BA2-A8DF-3FBB28ECE12CQ59136709-AD055EE6-8EE1-4B44-A618-C9B538B0A6A6
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Italian real-life experience of omalizumab.
@ast
Italian real-life experience of omalizumab.
@en
Italian real-life experience of omalizumab.
@nl
type
label
Italian real-life experience of omalizumab.
@ast
Italian real-life experience of omalizumab.
@en
Italian real-life experience of omalizumab.
@nl
prefLabel
Italian real-life experience of omalizumab.
@ast
Italian real-life experience of omalizumab.
@en
Italian real-life experience of omalizumab.
@nl
P2093
P1433
P1476
Italian real-life experience of omalizumab
@en
P2093
A Alessandrini
E Bucchioni
G Camiciottoli
M F Caiaffa
P304
P356
10.1016/J.RMED.2010.04.013
P577
2010-05-18T00:00:00Z